Oxford Biomedica (LON:OXB) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
by Amy Steele · The Cerbat GemOxford Biomedica plc (LON:OXB – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 591.25 and traded as low as GBX 443. Oxford Biomedica shares last traded at GBX 444.50, with a volume of 565,078 shares traded.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on OXB. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.
Get Our Latest Research Report on OXB
Oxford Biomedica Price Performance
The firm has a market cap of £537.45 million, a P/E ratio of -16.49 and a beta of 1.10. The firm’s fifty day simple moving average is GBX 537.62 and its 200 day simple moving average is GBX 587.80. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20.
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.